Avidity Biosciences Partners with Circular Genomics for Alzheimer's Diagnostics Innovation

Circular Genomics Relocates to Foster Innovations in Alzheimer's Diagnostics

Circular Genomics, a pioneering company specializing in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, has relocated its operations to Lilly Gateway Labs in San Diego, California. This strategic move is designed to enhance collaboration and spur innovation in the development of diagnostic and prognostic tools for Alzheimer's disease (AD). By partnering with Alexandria Real Estate Equities, Inc., Circular Genomics aims to capitalize on the neuroscience expertise offered by Eli Lilly and Company, facilitating the advancement of groundbreaking blood tests for AD.

Paul Sargeant, the CEO of Circular Genomics, emphasizes that this relocation marks a significant milestone for the company, as it positions them to utilize Lilly's extensive resources in a bid to accelerate their diagnostic programs. The company has already made strides in the field, with the launch of the early access program for MindLight™ in September 2024, which is the first blood test based on circRNA biomarkers aimed at predicting patient responses to selective serotonin reuptake inhibitors (SSRIs) in major depressive disorder (MDD). This initiative illustrates Circular Genomics' commitment to harnessing advanced biomarker technologies to improve patient outcomes.

The company’s pipeline includes a variety of novel circRNA assays, particularly one that accurately diagnoses patients who are at high risk for AD progression. These cutting-edge technologies are set to play a crucial role in enhancing patient stratification, improving the selection of clinical trial candidates, and monitoring both disease progression and treatment efficacy. By relocating to One Alexandria Square Megacampus, Circular Genomics aims to significantly bolster its mission of developing precise blood tests that leverage clinically validated, brain-derived biomarker assays. This move underscores the company’s dedication to addressing critical unmet needs in neurodegenerative disease diagnostics and improving patient care through innovative approaches.

In addition to the relocation, Circular Genomics' focus on circRNA biomarkers positions it at the forefront of the biotechnology sector, where the demand for precise diagnostic tools is paramount. The advancements in biomarker technologies not only promise to revolutionize the diagnosis and management of brain disorders but also pave the way for more personalized and effective treatment strategies.

As Circular Genomics integrates its operations within the vibrant ecosystem of Lilly Gateway Labs, the collaboration is expected to yield significant advancements in the understanding and treatment of Alzheimer's disease, potentially transforming the landscape of neurodegenerative disease diagnostics for years to come.